FEATURED NEWS

    MORE NEWS...

  • VG Life Sciences, Inc. Announces Filing of Form 10 with the SEC

    SANTA BARBARA, Calif., June 23, 2014 (GLOBE NEWSWIRE) — VG Life Sciences, Inc. (VGLS) is a publically traded biotechnology company focused on developing treatments for patients suffering from autoimmune and infectious diseases. VG Life Sciences is pleased to announce the filing of Form 10 with the Securities & Exchange Commission on June 19, 2014. Form […]


    READ MORE »
  • Q1 2014 Shareholder Update Letter

        Dear Shareholders, Here at VG Life Sciences, our goal is to move our revolutionary drug from the research laboratory, to pre-clinical studies, to clinical trials and to market expeditiously. The path is clear and we are working ever harder to increase your shareholder value. This is a company update since the beginning of […]


    READ MORE »
  • VG Life Sciences Inc. Moves to Restore Financial Accountability & Completes Prior Year Audits, Plans to File Form 10

    SANTA BARBARA, Calif., May 1, 2014 — VG Life Sciences (VGLS) is a publically traded biotechnology company focused on developing treatments for patients suffering from autoimmune and infectious diseases. Company Completes Prior Year Audits through December 31, 2013 VG Life Sciences is pleased to announce the completion of prior year audits. KWCO, PC Certified Public […]


    READ MORE »